ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in a Phase Ib clinical trial of IMM0306, a groundbreaking bispecific molecule for treating systemic lupus erythematosus (SLE). This innovative therapy targets both CD47 and CD20 on malignant B cells, aiming to improve therapeutic outcomes. The company holds global intellectual property and commercial rights for IMM0306, marking a significant step in its clinical development.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.